Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,208 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes. Results from PURSUIT.
Akkerhuis KM, Deckers JW, Boersma E, Harrington RA, Stepinska J, Mahaffey KW, Wilcox RG, Lincoff AM, Keltai M, Topol EJ, Califf RM, Simoons ML. Akkerhuis KM, et al. Among authors: topol ej. Eur Heart J. 2000 Mar;21(5):371-81. doi: 10.1053/euhj.1999.1743. Eur Heart J. 2000. PMID: 10666351 Clinical Trial.
Early angioplasty in acute coronary syndromes without persistent ST-segment elevation improves outcome but increases the need for six-month repeat revascularization: an analysis of the PURSUIT Trial. Platelet glycoprotein IIB/IIIA in Unstable angina: Receptor Suppression Using Integrilin Therapy.
Ronner E, Boersma E, Laarman GJ, Somsen GA, Harrington RA, Deckers JW, Topol EJ, Califf RM, Simoons ML. Ronner E, et al. Among authors: topol ej. J Am Coll Cardiol. 2002 Jun 19;39(12):1924-9. doi: 10.1016/s0735-1097(02)01897-1. J Am Coll Cardiol. 2002. PMID: 12084589 Free article. Clinical Trial.
Characteristics, treatment and outcome of patients with non-ST-elevation acute coronary syndromes and multivessel coronary artery disease: observations from PURSUIT (platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrelin therapy).
Breeman A, Mercado N, Lenzen M, van den Brand MM, Harrington RA, Califf RM, Topol EJ, Simoons ML, Boersma E; PURSUIT Investigators. Breeman A, et al. Among authors: topol ej. Cardiology. 2002;98(4):195-201. doi: 10.1159/000067321. Cardiology. 2002. PMID: 12566649 Clinical Trial.
Outcomes of patients with acute coronary syndromes and prior percutaneous coronary intervention: a pooled analysis of three randomized clinical trials.
Labinaz M, Mathias J, Pieper K, Granger CB, Lincoff AM, Moliterno DJ, Van de Werf F, Simes J, White HD, Simoons ML, Califf RM, Topol EJ, Armstrong PW, Harrington RA. Labinaz M, et al. Among authors: topol ej. Eur Heart J. 2005 Jan;26(2):128-36. doi: 10.1093/eurheartj/ehi061. Epub 2004 Dec 9. Eur Heart J. 2005. PMID: 15618068
Long-term results after the glycoprotein IIb/IIIa inhibitor abciximab in unstable angina: one-year survival in the GUSTO IV-ACS (Global Use of Strategies To Open Occluded Coronary Arteries IV--Acute Coronary Syndrome) Trial.
Ottervanger JP, Armstrong P, Barnathan ES, Boersma E, Cooper JS, Ohman EM, James S, Topol E, Wallentin L, Simoons ML; GUSTO IV-ACS Investigators. Ottervanger JP, et al. Circulation. 2003 Jan 28;107(3):437-42. doi: 10.1161/01.cir.0000046487.06811.5e. Circulation. 2003. PMID: 12551868 Clinical Trial.
Stroke in patients with acute coronary syndromes: incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina. Receptor suppression using integrilin therapy (PURSUIT) trial. The PURSUIT Investigators.
Mahaffey KW, Harrington RA, Simoons ML, Granger CB, Graffagnino C, Alberts MJ, Laskowitz DT, Miller JM, Sloan MA, Berdan LG, MacAulay CM, Lincoff AM, Deckers J, Topol EJ, Califf RM. Mahaffey KW, et al. Among authors: topol ej. Circulation. 1999 May 11;99(18):2371-7. doi: 10.1161/01.cir.99.18.2371. Circulation. 1999. PMID: 10318656 Clinical Trial.
1,208 results